½ÃÀ庸°í¼­
»óǰÄÚµå
1548176

¼¼°èÀÇ ½ÉÀå ¹ÙÀÌ¿À ÀÓÇöõÆ® µð¹ÙÀ̽º ½ÃÀå Á¶»ç º¸°í¼­ : »ê¾÷ ºÐ¼®, ±Ô¸ð, Á¡À¯À², ¼ºÀå, µ¿Çâ, ¿¹Ãø(2024-2032³â)

Global Cardiac Bio Implant Devices Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Value Market Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 174 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

½ÉÀå ¹ÙÀÌ¿À ÀÓÇöõÆ® µð¹ÙÀ̽º ½ÃÀåÀÇ ¼¼°è ¼ö¿ä´Â 2023³â 528¾ï 2,000¸¸ ´Þ·¯¿¡¼­ 2032³â¿¡´Â 1,308¾ï 9,000¸¸ ´Þ·¯ °¡±î¿î ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ÃßÁ¤µÇ¸ç, Á¶»ç ±â°£ÀÎ 2024-2032³âÀÇ CAGRÀº 10.61%ÀÔ´Ï´Ù.

½ÉÀå ¹ÙÀÌ¿À ÀÓÇöõÆ® µð¹ÙÀ̽º´Â ½ÉÀåÀÇ °íÀå³­ ºÎǰÀ» Áö¿øÇϰųª ±³Ã¼Çϵµ·Ï ¼³°èµÈ ÷´Ü ÀÇ·á¿ë ÀÓÇöõÆ®ÀÔ´Ï´Ù. ÀÌ·¯ÇÑ Àåºñ¿¡´Â »ýüÈí¼ö¼º ½ºÅÙÆ®, ½ÉÀå ÆÐÄ¡, ÇÕ¼º ½ÉÀå ÆÇ¸·°ú °°Àº »ýü °øÇÐ ÀÓÇöõÆ®°¡ Æ÷ÇÔµÇ¾î ½ÉÀå ±â´ÉÀ» º¹±¸Çϰųª °­È­ÇÕ´Ï´Ù. ±âÁ¸ ÀÓÇöõÆ®¿Í ´Þ¸® ¹ÙÀÌ¿À ÀÓÇöõÆ® Àåºñ´Â Á¾Á¾ Á¶Á÷ Àç»ý°ú ±â´É ȸº¹À» ÃËÁøÇÏ´Â »ý¹°ÇÐÀû Àç·á¿Í ¼³°è Ư¼ºÀ» ÅëÇÕÇϰí ÀÖ½À´Ï´Ù. ÀÚ¿¬ ½ÉÀå Á¶Á÷ÀÇ Æ¯¼º°ú ±â´ÉÀ» º¸´Ù Ãæ½ÇÇÏ°Ô ¸ð¹æÇÑ ¼Ö·ç¼ÇÀ» Á¦°øÇÔÀ¸·Î½á ȯÀÚÀÇ ¿¹Èĸ¦ °³¼±ÇÏ´Â °ÍÀ» ¸ñÇ¥·Î ÇÕ´Ï´Ù. ½ÉÀå ¹ÙÀÌ¿À ÀÓÇöõÆ®´Â °ü»óµ¿¸Æ Áúȯ, ½ÉÀå ÆÇ¸· Áúȯ, ½ÉºÎÀü µî ´Ù¾çÇÑ Áúȯ¿¡ »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ¹ÙÀÌ¿À ÀÓÇöõÆ®´Â ±âÁ¸ÀÇ ÀÓÇöõÆ® ±â¼ú°ú »ý¹°°øÇÐÀ» °áÇÕÇÏ¿© º¸´Ù È¿°úÀûÀ̰í Áö¼Ó°¡´ÉÇÑ Ä¡·á¸¦ Á¦°øÇÔÀ¸·Î½á ½ÉÀå Ä¡·á¿¡ ÀÖÀ¸¸ç, Áß¿äÇÑ ÁøÀüÀ» º¸À̰í ÀÖ½À´Ï´Ù.

½ÃÀå ¿ªÇÐ

½ÉÀå ¹ÙÀÌ¿À ÀÓÇöõÆ® µð¹ÙÀ̽º ½ÃÀåÀº °ü»óµ¿¸Æ Áúȯ ¹× ½ÉÀå ÆÇ¸· Áúȯ°ú °°Àº ½ÉÇ÷°ü ÁúȯÀÇ ¹ßº´·ü Áõ°¡·Î ÀÎÇØ ÷´Ü ÀÓÇöõÆ® ±â¼ú¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. Àü ¼¼°è¿¡¼­ ½ÉÀå ÁúȯÀÇ À¯º´·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó Ä¡·á ¿É¼ÇÀ» ´Ã¸®°í ȯÀÚÀÇ ¿¹Èĸ¦ °³¼±Çϱâ À§ÇØ ¹ÙÀÌ¿À ÀÓÇöõÆ®¿Í °°Àº Çõ½ÅÀûÀÎ ¼Ö·ç¼ÇÀÌ ÇÊ¿äÇÕ´Ï´Ù. ±â¼úÀÇ ¹ßÀüÀº ½ÃÀå¿¡ Å« ±âȸ¸¦ Á¦°øÇÕ´Ï´Ù. »ýüÈí¼ö¼º ½ºÅÙÆ® ¹× ÷´Ü ÇÕ¼º ½ÉÀå ÆÇ¸·ÀÇ °³¹ßÀº ½ÉÀå ÀÓÇöõÆ® ±â¼úÀÇ ºñ¾àÀûÀÎ ¹ßÀüÀ» ÀǹÌÇÕ´Ï´Ù. ÀÌ·¯ÇÑ Çõ½ÅÀº Àå±âÀûÀÎ ÇÕº´Áõ À§Çè °¨¼Ò¿Í ½ÉÀå Á¶Á÷°úÀÇ ÅëÇÕ¼º Çâ»ó°ú °°Àº ÀÌÁ¡À» Á¦°øÇÔÀ¸·Î½á ±âÁ¸ ÀÓÇöõÆ®¸¦ ´ëüÇÒ ¼ö ÀÖ´Â ¸Å·ÂÀûÀÎ ´ë¾ÈÀÌ µÇ°í ÀÖ½À´Ï´Ù.

¸ÂÃãÇü ÀÇ·á¿Í ȯÀÚ ¸ÂÃãÇü ¼Ö·ç¼Ç¿¡ ´ëÇÑ °ü½Éµµ ½ÃÀå ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ȯÀÚ °³°³ÀÎÀÇ Çʿ信 ¸Â°Ô Á¶Á¤ÇÒ ¼ö ÀÖ´Â ½ÉÀå ¹ÙÀÌ¿À ÀÓÇöõÆ®, ÀÎü Á¶Á÷°úÀÇ È£È¯¼ºÀ» ³ôÀ̱â À§ÇØ Ã·´Ü ¼ÒÀ縦 »ç¿ëÇÑ ÀÓÇöõÆ® µîÀÌ Àα⸦ ²ø°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¸ÂÃãÇü ÀÇ·á ¹× Á¤¹ÐÀÇ·á·ÎÀÇ ÀüȯÀº ÇコÄɾîÀÇ ±¤¹üÀ§ÇÑ µ¿Çâ°ú ÀÏÄ¡ÇÏ¸ç »õ·Î¿î ½ÃÀå ±âȸ¸¦ âÃâÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÀÇ·á ÀÎÇÁ¶óÀÇ È®´ë¿Í ½ÉÀå ¿¬±¸ ¹× °³¹ß¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡, ƯÈ÷ ½ÅÈï ½ÃÀå¿¡¼­ÀÇ ÅõÀÚ Áõ°¡°¡ ½ÃÀå ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ÀÇ·á ½Ã½ºÅÛÀÌ ¹ßÀüÇϰí ÷´Ü ½ÉÀå ±â¼ú¿¡ ´ëÇÑ Á¢±Ù¼ºÀÌ Çâ»óµÊ¿¡ µû¶ó ½ÉÀå ¹ÙÀÌ¿À ÀÓÇöõÆ® µð¹ÙÀ̽ºÀÇ Ã¤ÅÃÀÌ Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±×·¯³ª ½ÉÀå ¹ÙÀÌ¿À ÀÓÇöõÆ® µð¹ÙÀ̽ºÀÇ ³ôÀº °¡°Ý°ú µµÀÔÀÇ º¹À⼺Àº ½ÃÀå ¼ºÀåÀ» ÀúÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ ±ÔÁ¦ ¹®Á¦¿Í ´ë±Ô¸ð ÀÓ»ó½ÃÇèÀÇ Çʿ伺Àº »õ·Î¿î ¹ÙÀÌ¿À ÀÓÇöõÆ® ±â¼úÀÇ °³¹ß ¹× äÅÃÀ» ¹æÇØÇÏ°í ½ÃÀå È®´ë¸¦ Á¦ÇÑÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ Á¶»ç º¸°í¼­´Â Porter's Five Forces ¸ðµ¨, ½ÃÀå ¸Å·Âµµ ºÐ¼®, ¹ë·ùüÀÎ ºÐ¼®À» ´Ù·ç°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÅøÀº »ê¾÷ ±¸Á¶¸¦ ¸íÈ®ÇÏ°Ô ÆÄ¾ÇÇÏ°í ¼¼°è ¼öÁØ¿¡¼­ °æÀïÀÇ ¸Å·ÂÀ» Æò°¡ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ¶ÇÇÑ ÀÌ·¯ÇÑ ÅøÀº ¼¼°èÀÇ ½ÉÀå ¹ÙÀÌ¿À ÀÓÇöõÆ® µð¹ÙÀ̽º ½ÃÀå¿¡¼­ °¢ ºÎ¹®À» Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ½ÉÀå ¹ÙÀÌ¿À ÀÓÇöõÆ® µð¹ÙÀ̽º »ê¾÷ÀÇ ¼ºÀå°ú µ¿ÇâÀº ÀÌ Á¶»ç¿¡ ´ëÇÑ ÀüüÀûÀÎ Á¢±Ù ¹æ½ÄÀ» Á¦°øÇÕ´Ï´Ù.

½ÃÀå ¼¼ºÐÈ­

½ÉÀå ¹ÙÀÌ¿À ÀÓÇöõÆ® ±â±â ½ÃÀå º¸°í¼­´Â ±¹°¡ ¹× Áö¿ªº° ºÎ¹®¿¡ ´ëÇÑ »ó¼¼ÇÑ µ¥ÀÌÅ͸¦ Á¦°øÇÔÀ¸·Î½á Àü·« ´ã´çÀÚ°¡ °¢ Á¦Ç° ¹× ¼­ºñ½ºÀÇ Å¸±êÃþÀ» ½Äº°Çϰí ÇâÈÄ ºñÁî´Ï½º ±âȸ¸¦ Æ÷ÂøÇÒ ¼ö ÀÖµµ·Ï µ½½À´Ï´Ù.

Á¦Ç°º°

  • ½ÉÀå ±¸Á¶ ÀÓÇöõÆ®
  • ½ºÅÙÆ® ¹× °ü·Ã ÀÓÇöõÆ®
  • ÆäÀÌ½Ì Àåºñ

Áúº´º°

  • ½É±Ù ÇãÇ÷
  • ±Þ¼º ½É±Ù°æ»öÁõ
  • ºÎÁ¤¸Æ
  • ¿ïÇ÷¼º½ÉºÎÀü(CHF)
  • Çù½ÉÁõ(AP)
  • ½É±ÙÁõ
  • ´ëµ¿¸Æ·ù
  • ±âŸ

¼ö±âº°

  • Ç÷°ü ¼ºÇü¼ú
  • ½ÉÀå ÆÇ¸· ¼ö¸® ¶Ç´Â ±³Ã¼
  • °³Èä ½ÉÀå ¼ö¼ú
  • Àúħ½ÀÀû ½ÉÀå ¼ö¼ú
  • ½ÉÀå À絿±âÈ­ Ä¡·á(CRT)(CRT)
  • ±âŸ

Áö¿ª ºÐ¼®

ÀÌ ¼½¼Ç¿¡¼­´Â ºÏ¹Ì, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ½ÉÀå ¹ÙÀÌ¿À ÀÓÇöõÆ® µð¹ÙÀ̽º ½ÃÀåÀÇ ÇöÀç ¹× ¹Ì·¡ ¼ö¿ä¸¦ °­Á¶ÇÏ´Â Áö¿ª Àü¸ÁÀ» ´Ù·ì´Ï´Ù. ¶ÇÇÑ ÀÌ º¸°í¼­´Â ¸ðµç ÁÖ¿ä Áö¿ªÀÇ °³º° ¿ëµµ ºÎ¹® ¼ö¿ä, ÃßÁ¤ ¹× ¿¹Ãø¿¡ ÃÊÁ¡À» ¸ÂÃß¾ú½À´Ï´Ù.

Ä¿½ºÅÒ ¿ä°ÇÀÌ ÀÖ´Â °æ¿ì, ¹®ÀÇÇØÁֽñ⠹ٶø´Ï´Ù. ´ç»çÀÇ Á¶»ç ÆÀÀº °í°´ÀÇ ¿ä±¸¿¡ µû¶ó Ä¿½ºÅ͸¶ÀÌÁî ¸®Æ÷Æ®¸¦ Á¦°øÇÒ ¼ö ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå °³¿ä

  • ½ÃÀåÀÇ ÇÏÀ̶óÀÌÆ®
  • ¼¼°è ½ÃÀå ½º³À¼ô

Á¦3Àå ½ÉÀå ¹ÙÀÌ¿À ÀÓÇöõÆ® µð¹ÙÀ̽º - »ê¾÷ ºÐ¼®

  • ¼­·Ð : ½ÃÀå ¿ªÇÐ
  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
  • ½ÃÀå ±âȸ
  • ¾÷°è µ¿Çâ
  • Porter's Five Forces ºÐ¼®
  • ½ÃÀåÀÇ ¸Å·Â ºÐ¼®

Á¦4Àå ¹ë·ùüÀÎ ºÐ¼®

  • ¹ë·ùüÀÎ ºÐ¼®
  • ¿øÀç·á ºÐ¼®
    • ¿øÀç·á ¸®½ºÆ®
    • ¿øÀç·á Á¦Á¶¾÷ü ¸®½ºÆ®
    • ÁÖ¿ä ¿øÀç·áÀÇ °¡°Ý µ¿Çâ
  • ÀáÀçÀû ¹ÙÀÌ¾î ¸®½ºÆ®
  • ¸¶ÄÉÆÃ Ã¤³Î
    • ´ÙÀÌ·ºÆ® ¸¶ÄÉÆÃ
    • ÀδÙÀÌ·ºÆ® ¸¶ÄÉÆÃ
    • ¸¶ÄÉÆÃ Ã¤³Î ¹ßÀü µ¿Çâ

Á¦5Àå ¼¼°èÀÇ ½ÉÀå ¹ÙÀÌ¿À ÀÓÇöõÆ® µð¹ÙÀ̽º ½ÃÀå ºÐ¼® : Á¦Ç°º°

  • Á¦Ç°º° °³¿ä
  • Á¦Ç°º° °ú°Å ¹× ¿¹Ãø µ¥ÀÌÅÍ ºÐ¼®
  • ½ÉÀå ±¸Á¶ ÀÓÇöõÆ®
  • ½ºÅÙÆ® ¹× °ü·Ã ÀÓÇöõÆ®
  • ÆäÀÌ½Ì µð¹ÙÀ̽º

Á¦6Àå ¼¼°èÀÇ ½ÉÀå ¹ÙÀÌ¿À ÀÓÇöõÆ® µð¹ÙÀ̽º ½ÃÀå ºÐ¼® : Áúȯº°

  • Áúȯº° °³¿ä
  • Áúȯº° °ú°Å ¹× ¿¹Ãø µ¥ÀÌÅÍ ºÐ¼®
  • ½É±ÙÇãÇ÷
  • ±Þ¼º ½É±Ù°æ»ö
  • ºÎÁ¤¸Æ
  • ¿ïÇ÷¼º½ÉºÎÀü(CHF)
  • Çù½ÉÁõ(AP)
  • ½É±ÙÁõ
  • ´ëµ¿¸Æ·ù
  • ±âŸ

Á¦7Àå ¼¼°èÀÇ ½ÉÀå ¹ÙÀÌ¿À ÀÓÇöõÆ® µð¹ÙÀ̽º ½ÃÀå ºÐ¼® : ½Ã¼úº°

  • ½Ã¼úº° °³¿ä
  • ½Ã¼úº° °ú°Å ¹× ¿¹Ãø µ¥ÀÌÅÍ ºÐ¼®
  • Ç÷°ü¼ºÇü¼ú
  • ½ÉÀåÆÇ¸· ¼öº¹ ¶Ç´Â ±³È¯
  • °³½É¼ú
  • Àúħ½À ½ÉÀå¼ö¼ú
  • ½ÉÀåÀ絿±â ¿ä¹ý(CRT)
  • ±âŸ

Á¦8Àå ¼¼°èÀÇ ½ÉÀå ¹ÙÀÌ¿À ÀÓÇöõÆ® µð¹ÙÀ̽º ½ÃÀå ºÐ¼® : Áö¿ªº°

  • Áö¿ªº° Àü¸Á
  • ¼­·Ð
  • ºÏ¹ÌÀÇ ÆÇ¸Å ºÐ¼®
    • °³¿ä, ½ÇÀû°ú ¿¹Ãø
    • ºÏ¹Ì : ºÎ¹®º°
    • ºÏ¹Ì ±¹°¡º°
    • ¹Ì±¹
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
  • À¯·´ ÆÇ¸Å ºÐ¼®
    • °³¿ä, ½ÇÀû°ú ¿¹Ãø
    • À¯·´ ºÎ¹®º°
    • À¯·´ ±¹°¡º°
    • ¿µ±¹
    • ÇÁ¶û½º
    • µ¶ÀÏ
    • ÀÌÅ»¸®¾Æ
    • ·¯½Ã¾Æ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç ÆÇ¸Å ºÐ¼®
    • °³¿ä, ½ÇÀû°ú ¿¹Ãø
    • ¾Æ½Ã¾ÆÅÂÆò¾ç ºÎ¹®º°
    • ¾Æ½Ã¾ÆÅÂÆò¾ç ±¹°¡º°
    • Áß±¹
    • Àεµ
    • ÀϺ»
    • Çѱ¹
    • È£ÁÖ
    • µ¿³²¾Æ½Ã¾Æ
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä« ÆÇ¸Å ºÐ¼®
    • °³¿ä, ½ÇÀû°ú ¿¹Ãø
    • ¶óƾ¾Æ¸Þ¸®Ä« ºÎ¹®º°
    • ¶óƾ¾Æ¸Þ¸®Ä« ±¹°¡º°
    • ºê¶óÁú
    • ¾Æ¸£ÇîÆ¼³ª
    • Æä·ç
    • Ä¥·¹
    • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« ÆÇ¸Å ºÐ¼®
    • °³¿ä, ½ÇÀû°ú ¿¹Ãø
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« ºÎ¹®º°
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« ±¹°¡º° ¸®½ºÆ®
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®
    • À̽º¶ó¿¤
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦9Àå ½ÉÀå ¹ÙÀÌ¿À ÀÓÇöõÆ® µð¹ÙÀ̽º ±â¾÷ÀÇ °æÀï ±¸µµ

  • ½ÉÀå ¹ÙÀÌ¿À ÀÓÇöõÆ® ½ÃÀå °æÀï
  • ÆÄÆ®³Ê½Ê/Á¦ÈÞ/ÇùÁ¤
  • ÇÕº´¡¤Àμö
  • ½ÅÁ¦Ç° ¹ß¸Å
  • ±âŸ °³¹ß

Á¦10Àå ±â¾÷ °³¿ä

  • »óÀ§ ±â¾÷ÀÇ ½ÃÀå Á¡À¯À² ºÐ¼®
  • ½ÃÀå ÁýÁßµµ
  • Abbott
  • Edwards Lifesciences Corporation
  • Johnson & Johnson Services Inc.
  • LivaNova PLC
  • Medtronic
  • Boston Scientific Corporation
  • MicroPort Scientific Corporation
  • Mayo Foundation For Medical Education And Research(MFMER)
  • ClearPoint Neuro Inc.
  • Imricor
  • Biotronik
  • Bentley
  • Elestim-Cardio
  • QualiMed
  • Medico S.P.A.
  • Lepu Medical Technology(Beijing) Co. Ltd.
  • W. L. Gore & Associates Inc
KSA 24.10.02

The global demand for Cardiac Bio Implant Devices Market is presumed to reach the market size of nearly USD 130.89 Billion by 2032 from USD 52.82 Billion in 2023 with a CAGR of 10.61% under the study period 2024-2032.

Cardiac bio-implant devices are advanced medical implants designed to support or replace malfunctioning components of the heart. These devices include bioengineered implants such as bioresorbable stents, cardiac patches, and synthetic heart valves to repair or enhance heart function. Unlike traditional implants, bio implant devices often integrate biological materials or design features that promote tissue regeneration and function restoration. They aim to improve patient outcomes by offering solutions that more closely mimic natural heart tissue properties and functionality. Cardiac bio implants are used in various conditions, including coronary artery disease, heart valve disorders, and heart failure. They represent a significant advancement in cardiac care by combining bioengineering with traditional implant technologies to provide more effective and sustainable treatments.

MARKET DYNAMICS

The cardiac bio implant devices market is driven by the increasing incidence of cardiovascular diseases, including coronary artery disease and heart valve disorders, which fuels the demand for advanced implant technologies. The growing prevalence of heart conditions worldwide necessitates innovative solutions like bio implants to enhance treatment options and improve patient outcomes. Technological advancements are creating significant opportunities within the market. The development of bioresorbable stents and advanced synthetic heart valves represents a leap forward in cardiac implant technology. These innovations offer benefits such as reduced risk of long-term complications and improved integration with heart tissue, making them attractive alternatives to traditional implants.

The focus on personalized medicine and patient-specific solutions is also driving market growth. Cardiac bio implants that can be tailored to individual patient needs or that use advanced materials for better compatibility with human tissue are gaining traction. This shift towards personalized and precision medicine aligns with broader trends in healthcare, creating additional market opportunities. Moreover, expanding healthcare infrastructure and increasing investment in cardiac research and development, particularly in emerging markets, contribute to market growth. As healthcare systems evolve and access to advanced cardiac technologies improves, the adoption of cardiac bio implant devices is expected to rise. However, the high cost of cardiac bio implant devices and the complexity of their implementation may restrain market growth. Additionally, regulatory challenges and the need for extensive clinical trials can impede the development and adoption of new bio implant technologies, potentially limiting market expansion.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Cardiac Bio Implant Devices. The growth and trends of Cardiac Bio Implant Devices industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Cardiac Bio Implant Devices market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Product

  • Structural Cardiac Implants
  • Stents and Related Implants
  • A Pacing Device

By Disease

  • Myocardial Ischemia
  • Acute Myocardial Infarction
  • Arrhythmias
  • Congestive Heart Failure (CHF)
  • Angina Pectoris (AP)
  • Cardiomyopathy
  • Aortic Aneurism
  • Others

By Procedure

  • Angioplasty
  • Heart Valve Repair or Replacement
  • Open Heart Surgery
  • Minimally Invasive Heart Surgery
  • Cardiac Resynchronization Therapy (CRT)
  • Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Cardiac Bio Implant Devices market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Cardiac Bio Implant Devices market include Abbott, Edwards Lifesciences Corporation, Johnson & Johnson Services Inc., LivaNova PLC, Medtronic, Boston Scientific Corporation, MicroPort Scientific Corporation, Mayo Foundation For Medical Education And Research (MFMER), ClearPoint Neuro Inc., Imricor, Biotronik, Bentley, Elestim-Cardio, QualiMed, Medico S.P.A., Lepu Medical Technology (Beijing)Co. Ltd., W. L. Gore & Associates Inc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Report Description
    • 1.1.1 Objective
    • 1.1.2 Target Audience
    • 1.1.3 Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1 Market Research Process
    • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3. CARDIAC BIO IMPLANT DEVICES - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Product
    • 3.7.2 Market Attractiveness Analysis By Disease
    • 3.7.3 Market Attractiveness Analysis By Procedure
    • 3.7.4 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1 List of Raw Materials
    • 4.2.2 Raw Material Manufactures List
    • 4.2.3 Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1 Direct Marketing
    • 4.4.2 Indirect Marketing
    • 4.4.3 Marketing Channel Development Trend

5. GLOBAL CARDIAC BIO IMPLANT DEVICES MARKET ANALYSIS BY PRODUCT

  • 5.1. Overview By Product
  • 5.2. Historical and Forecast Data Analysis By Product
  • 5.3. Structural Cardiac Implants Historic and Forecast Sales By Regions
  • 5.4. Stents and Related Implants Historic and Forecast Sales By Regions
  • 5.5. A Pacing Device Historic and Forecast Sales By Regions

6. GLOBAL CARDIAC BIO IMPLANT DEVICES MARKET ANALYSIS BY DISEASE

  • 6.1. Overview By Disease
  • 6.2. Historical and Forecast Data Analysis By Disease
  • 6.3. Myocardial Ischemia Historic and Forecast Sales By Regions
  • 6.4. Acute Myocardial Infarction Historic and Forecast Sales By Regions
  • 6.5. Arrhythmias Historic and Forecast Sales By Regions
  • 6.6. Congestive Heart Failure (CHF) Historic and Forecast Sales By Regions
  • 6.7. Angina Pectoris (AP) Historic and Forecast Sales By Regions
  • 6.8. Cardiomyopathy Historic and Forecast Sales By Regions
  • 6.9. Aortic Aneurism Historic and Forecast Sales By Regions
  • 6.10. Others Historic and Forecast Sales By Regions

7. GLOBAL CARDIAC BIO IMPLANT DEVICES MARKET ANALYSIS BY PROCEDURE

  • 7.1. Overview By Procedure
  • 7.2. Historical and Forecast Data Analysis By Procedure
  • 7.3. Angioplasty Historic and Forecast Sales By Regions
  • 7.4. Heart Valve Repair or Replacement Historic and Forecast Sales By Regions
  • 7.5. Open Heart Surgery Historic and Forecast Sales By Regions
  • 7.6. Minimally Invasive Heart Surgery Historic and Forecast Sales By Regions
  • 7.7. Cardiac Resynchronization Therapy (CRT) Historic and Forecast Sales By Regions
  • 7.8. Others Historic and Forecast Sales By Regions

8. GLOBAL CARDIAC BIO IMPLANT DEVICES MARKET ANALYSIS BY GEOGRAPHY

  • 8.1. Regional Outlook
  • 8.2. Introduction
  • 8.3. North America Sales Analysis
    • 8.3.1 Overview, Historic and Forecast Data Sales Analysis
    • 8.3.2 North America By Segment Sales Analysis
    • 8.3.3 North America By Country Sales Analysis
    • 8.3.4 United States Sales Analysis
    • 8.3.5 Canada Sales Analysis
    • 8.3.6 Mexico Sales Analysis
  • 8.4. Europe Sales Analysis
    • 8.4.1 Overview, Historic and Forecast Data Sales Analysis
    • 8.4.2 Europe By Segment Sales Analysis
    • 8.4.3 Europe By Country Sales Analysis
    • 8.4.4 United Kingdom Sales Analysis
    • 8.4.5 France Sales Analysis
    • 8.4.6 Germany Sales Analysis
    • 8.4.7 Italy Sales Analysis
    • 8.4.8 Russia Sales Analysis
    • 8.4.9 Rest Of Europe Sales Analysis
  • 8.5. Asia Pacific Sales Analysis
    • 8.5.1 Overview, Historic and Forecast Data Sales Analysis
    • 8.5.2 Asia Pacific By Segment Sales Analysis
    • 8.5.3 Asia Pacific By Country Sales Analysis
    • 8.5.4 China Sales Analysis
    • 8.5.5 India Sales Analysis
    • 8.5.6 Japan Sales Analysis
    • 8.5.7 South Korea Sales Analysis
    • 8.5.8 Australia Sales Analysis
    • 8.5.9 South East Asia Sales Analysis
    • 8.5.10 Rest Of Asia Pacific Sales Analysis
  • 8.6. Latin America Sales Analysis
    • 8.6.1 Overview, Historic and Forecast Data Sales Analysis
    • 8.6.2 Latin America By Segment Sales Analysis
    • 8.6.3 Latin America By Country Sales Analysis
    • 8.6.4 Brazil Sales Analysis
    • 8.6.5 Argentina Sales Analysis
    • 8.6.6 Peru Sales Analysis
    • 8.6.7 Chile Sales Analysis
    • 8.6.8 Rest of Latin America Sales Analysis
  • 8.7. Middle East & Africa Sales Analysis
    • 8.7.1 Overview, Historic and Forecast Data Sales Analysis
    • 8.7.2 Middle East & Africa By Segment Sales Analysis
    • 8.7.3 Middle East & Africa By Country Sales Analysis
    • 8.7.4 Saudi Arabia Sales Analysis
    • 8.7.5 UAE Sales Analysis
    • 8.7.6 Israel Sales Analysis
    • 8.7.7 South Africa Sales Analysis
    • 8.7.8 Rest Of Middle East And Africa Sales Analysis

9. COMPETITIVE LANDSCAPE OF THE CARDIAC BIO IMPLANT DEVICES COMPANIES

  • 9.1. Cardiac Bio Implant Devices Market Competition
  • 9.2. Partnership/Collaboration/Agreement
  • 9.3. Merger And Acquisitions
  • 9.4. New Product Launch
  • 9.5. Other Developments

10. COMPANY PROFILES OF CARDIAC BIO IMPLANT DEVICES INDUSTRY

  • 10.1. Top Companies Market Share Analysis
  • 10.2. Market Concentration Rate
  • 10.3. Abbott
    • 10.3.1 Company Overview
    • 10.3.2 Company Revenue
    • 10.3.3 Products
    • 10.3.4 Recent Developments
  • 10.4. Edwards Lifesciences Corporation
    • 10.4.1 Company Overview
    • 10.4.2 Company Revenue
    • 10.4.3 Products
    • 10.4.4 Recent Developments
  • 10.5. Johnson & Johnson Services Inc.
    • 10.5.1 Company Overview
    • 10.5.2 Company Revenue
    • 10.5.3 Products
    • 10.5.4 Recent Developments
  • 10.6. LivaNova PLC
    • 10.6.1 Company Overview
    • 10.6.2 Company Revenue
    • 10.6.3 Products
    • 10.6.4 Recent Developments
  • 10.7. Medtronic
    • 10.7.1 Company Overview
    • 10.7.2 Company Revenue
    • 10.7.3 Products
    • 10.7.4 Recent Developments
  • 10.8. Boston Scientific Corporation
    • 10.8.1 Company Overview
    • 10.8.2 Company Revenue
    • 10.8.3 Products
    • 10.8.4 Recent Developments
  • 10.9. MicroPort Scientific Corporation
    • 10.9.1 Company Overview
    • 10.9.2 Company Revenue
    • 10.9.3 Products
    • 10.9.4 Recent Developments
  • 10.10. Mayo Foundation For Medical Education And Research (MFMER)
    • 10.10.1 Company Overview
    • 10.10.2 Company Revenue
    • 10.10.3 Products
    • 10.10.4 Recent Developments
  • 10.11. ClearPoint Neuro Inc.
    • 10.11.1 Company Overview
    • 10.11.2 Company Revenue
    • 10.11.3 Products
    • 10.11.4 Recent Developments
  • 10.12. Imricor
    • 10.12.1 Company Overview
    • 10.12.2 Company Revenue
    • 10.12.3 Products
    • 10.12.4 Recent Developments
  • 10.13. Biotronik
    • 10.13.1 Company Overview
    • 10.13.2 Company Revenue
    • 10.13.3 Products
    • 10.13.4 Recent Developments
  • 10.14. Bentley
    • 10.14.1 Company Overview
    • 10.14.2 Company Revenue
    • 10.14.3 Products
    • 10.14.4 Recent Developments
  • 10.15. Elestim-Cardio
    • 10.15.1 Company Overview
    • 10.15.2 Company Revenue
    • 10.15.3 Products
    • 10.15.4 Recent Developments
  • 10.16. QualiMed
    • 10.16.1 Company Overview
    • 10.16.2 Company Revenue
    • 10.16.3 Products
    • 10.16.4 Recent Developments
  • 10.17. Medico S.P.A.
    • 10.17.1 Company Overview
    • 10.17.2 Company Revenue
    • 10.17.3 Products
    • 10.17.4 Recent Developments
  • 10.18. Lepu Medical Technology (Beijing) Co. Ltd.
    • 10.18.1 Company Overview
    • 10.18.2 Company Revenue
    • 10.18.3 Products
    • 10.18.4 Recent Developments
  • 10.19. W. L. Gore & Associates Inc
    • 10.19.1 Company Overview
    • 10.19.2 Company Revenue
    • 10.19.3 Products
    • 10.19.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies

»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦